康希诺：重组三价脊髓灰质炎疫苗（Sf-RVN细胞）获得药物临床试验批准通知书

Core Viewpoint - CanSino Biologics has received approval from the National Medical Products Administration for the clinical trial of its trivalent inactivated poliovirus vaccine (Sf-RVN cells), indicating progress in vaccine development and potential market entry [1] Group 1: Company Developments - CanSino Biologics announced the receipt of the clinical trial approval notice for its trivalent inactivated poliovirus vaccine [1] - The vaccine is developed using protein structure design and VLP assembly technology, ensuring it does not contain viral genetic material, which contributes to its safety and immunogenicity [1] - The vaccine is currently undergoing Phase I/II clinical trials in Indonesia [1] Group 2: Regulatory and Clinical Trial Information - The approval from the National Medical Products Administration allows CanSino to proceed with clinical trials in accordance with national drug registration regulations and requirements [1]